Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study
Copyright © 2022 Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Publicado por Elsevier España, S.L.U. All rights reserved..
INTRODUCTION: COVID-19 induces coagulopathy associated with an increase of thromboembolic events. Due to the lack of agreement on recommendations for thromboprophylactic management, the aim of this study was to study the dosages of LMWH used in critically ill COVID-19 patients assessing the effect on their outcome.
METHODS: We evaluated data of the Reg-COVID19. According to LMWH dose two groups were analyzed: prophylaxis and treatment. Primary outcome was the relationship of LMWH dosage with mortality. Secondary outcomes included the incidence of thrombotic and bleeding events, length of ICU stay, invasive mechanical ventilation, and thrombotic and inflammatory parameters.
RESULTS: Data of 720 patients were analyzed, 258 in the prophylaxis group and 462 in the treatment group. C Reactive Protein, invasive mechanical ventilation, tocilizumab and corticosteroid treatments were related with the choice of LMWH dose. Hemorrhagic events (66/720, 9.2%) and thrombotic complications (69/720, 9.6%) were similar in both groups (p = .819 and p = .265), as was the time course of the thrombotic events, earlier than hemorrhagic ones (9 [3-18] and 12 [6-19] days respectively). Mortality was lower in prophylaxis group (25.2% versus 35.1%), but once an inverse probability weighting model was applied, we found no effect of LMWH dose.
CONCLUSION: We found no benefit or harm with the administration of therapeutic or prophylactic LMWH dose in COVID19 critically ill patients. With a similar rate of hemorrhagic or thrombotic events, the LMWH dose had no influence on mortality. More studies are needed to determine the optimal thromboprophylaxis protocol for critically ill patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Revista espanola de anestesiologia y reanimacion - 70(2023), 3 vom: 01. März, Seite 129-139 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferrandis, R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.04.2023 Date Revised 20.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.redare.2023.02.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353488089 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353488089 | ||
| 003 | DE-627 | ||
| 005 | 20231226060120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.redare.2023.02.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353488089 | ||
| 035 | |a (NLM)36842685 | ||
| 035 | |a (PII)S2341-1929(23)00049-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferrandis, R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2023 | ||
| 500 | |a Date Revised 20.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION: COVID-19 induces coagulopathy associated with an increase of thromboembolic events. Due to the lack of agreement on recommendations for thromboprophylactic management, the aim of this study was to study the dosages of LMWH used in critically ill COVID-19 patients assessing the effect on their outcome | ||
| 520 | |a METHODS: We evaluated data of the Reg-COVID19. According to LMWH dose two groups were analyzed: prophylaxis and treatment. Primary outcome was the relationship of LMWH dosage with mortality. Secondary outcomes included the incidence of thrombotic and bleeding events, length of ICU stay, invasive mechanical ventilation, and thrombotic and inflammatory parameters | ||
| 520 | |a RESULTS: Data of 720 patients were analyzed, 258 in the prophylaxis group and 462 in the treatment group. C Reactive Protein, invasive mechanical ventilation, tocilizumab and corticosteroid treatments were related with the choice of LMWH dose. Hemorrhagic events (66/720, 9.2%) and thrombotic complications (69/720, 9.6%) were similar in both groups (p = .819 and p = .265), as was the time course of the thrombotic events, earlier than hemorrhagic ones (9 [3-18] and 12 [6-19] days respectively). Mortality was lower in prophylaxis group (25.2% versus 35.1%), but once an inverse probability weighting model was applied, we found no effect of LMWH dose | ||
| 520 | |a CONCLUSION: We found no benefit or harm with the administration of therapeutic or prophylactic LMWH dose in COVID19 critically ill patients. With a similar rate of hemorrhagic or thrombotic events, the LMWH dose had no influence on mortality. More studies are needed to determine the optimal thromboprophylaxis protocol for critically ill patients | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Complicaciones hemorrágicas | |
| 650 | 4 | |a Complicaciones trombóticas | |
| 650 | 4 | |a Critically ill patients | |
| 650 | 4 | |a Haemorrhagic complications | |
| 650 | 4 | |a Heparina de bajo peso molecular | |
| 650 | 4 | |a Low-molecular-weight heparin | |
| 650 | 4 | |a Paciente crítico | |
| 650 | 4 | |a Thromboprohylaxis | |
| 650 | 4 | |a Thrombotic complications | |
| 650 | 4 | |a Tromboprofilaxis | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 700 | 1 | |a Escontrela, B |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrando, C |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández, M |e verfasserin |4 aut | |
| 700 | 1 | |a Herrera, J |e verfasserin |4 aut | |
| 700 | 1 | |a Hidalgo, F |e verfasserin |4 aut | |
| 700 | 1 | |a Librero, J |e verfasserin |4 aut | |
| 700 | 1 | |a Llau, J V |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, A |e verfasserin |4 aut | |
| 700 | 1 | |a Pajares, A |e verfasserin |4 aut | |
| 700 | 1 | |a Tapia, B |e verfasserin |4 aut | |
| 700 | 1 | |a Arruti, E |e verfasserin |4 aut | |
| 700 | 1 | |a Bassas, E |e verfasserin |4 aut | |
| 700 | 1 | |a Blasi, A |e verfasserin |4 aut | |
| 700 | 1 | |a Calvo, A |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 Spanish ICU Network Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de anestesiologia y reanimacion |d 2012 |g 70(2023), 3 vom: 01. März, Seite 129-139 |w (DE-627)NLM222859482 |x 2341-1929 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2023 |g number:3 |g day:01 |g month:03 |g pages:129-139 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.redare.2023.02.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2023 |e 3 |b 01 |c 03 |h 129-139 | ||